Carocell Bio Limited (“Carocell”) is developing novel therapeutics to more safely & effectively treat life threatening and disabling inflammatory conditions such as inflammatory bowel disease (IBD), atopic dermatitis (AD, eczema), psoriasis and burns.
Inflammation refers to a biological response to stimuli, interpreted by the body to have a potentially harmful effect. In certain situations, such as after injury, inflammation is a normal response. However, inflammatory diseases result in the immune system attacking the body’s own cells or tissues and may cause abnormal inflammation resulting in chronic pain, swelling, stiffness and damage to normal tissues.
Carocell’s novel medicines are short proteins (“peptides”) that are delivered into human cells using a patented, safe nano-polymer delivery technology. We have shown them to switch off inflammation in a recognised cellular model and also prevent the activation of inflammation. These short peptides that will be broken down into simple and naturally occurring amino acids, are highly active and exquisitely specific inflammation blockers, so only tiny doses will be required to cure serious inflammatory diseases.
Carocell is an ambitious company aiming to be revenue-generating within 3 years.
This video is of Dr. Mike Davies discussing Carocell Bio's work with Christine Corrado of Proactive Investors.
As of august 14, 2019 Bridge Biotec became Carocell Bio Limited.
If you would like to make a donation to Carocell Bio to help us advance our research into inflammation treatments, please use the donate button below.